The dual GIP/GLP-1 mechanism of tirzepatide versus semaglutide does not guarantee worse digestive effects for every individual, even though the population-level data suggests slightly higher incidence
A literature search was performed identifying clinical trials of semaglutide published until 01 Dec 2023
An important link with carnitine derives from chronic hepatitis B patients
The researchers concluded that GLP-1 therapy for obesity should include resistance training, optimal protein intake, and if needed, specific nutrients and pharmacological interventions to preserve muscle mass
In this review, as part of a supplement on semaglutide, we will detail the safety aspects of this drug
Consultation and Assessment Before starting Tirzepatide, its essential to consult with a healthcare provider